Abcellera Biologics Inc (ABCL) — Cash Flow Quality Index
Abcellera Biologics Inc (ABCL) has a Cash Flow Quality Index of -4.76x as of September 2022. Operating cash flow of $-126.79 Million is below net income of $26.62 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore debt repayment capacity of Abcellera Biologics Inc to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Abcellera Biologics Inc Cash Flow Quality Index (2018–2022)
Historical Cash Flow Quality Index for Abcellera Biologics Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Abcellera Biologics Inc (ABCL) cash conversion ratio.
Annual Cash Flow Quality Index for Abcellera Biologics Inc (2018–2022)
Year-by-year earnings quality comparison for Abcellera Biologics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 1.75x | $277.36 Million | $158.52 Million | ▲ +9.8% |
| 2021 | 1.59x | $244.58 Million | $153.46 Million | ▲ +735.3% |
| 2020 | 0.19x | $22.69 Million | $118.92 Million | ▼ -98.3% |
| 2018 | 11.54x | $3.56 Million | $309.00K | — |